Cytotoxicity of α-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia
- 1 March 1998
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (5) , 753-759
- https://doi.org/10.1038/bjc.1998.123
Abstract
The high linear energy transfer, alpha-particle-emitting radionuclide astatine-211 (211At) is of interest for certain therapeutic applications; however, because of the 55- to 70-microm path length of its alpha-particles, achieving homogeneous tracer distribution is critical. Hyperthermia may enhance the therapeutic efficacy of alpha-particle endoradiotherapy if it can improve tracer distribution. In this study, we have investigated whether hyperthermia increased the cytotoxicity of an 211At-labelled monoclonal antibody (MAb) in tumour spheroids with a radius (approximately 100 microm) greater than the range of 211At alpha-particles. Hyperthermia for 1 h at 42 degrees C was used because this treatment itself resulted in no regrowth delay. Radiolabelled chimeric MAb 81C6 reactive with the extracellular matrix antigen tenascin was added to spheroids grown from the D-247 MG human glioma cell line at activity concentrations ranging from 0.125 to 250 kBq ml(-1). A significant regrowth delay was observed at 125 and 250 kBq ml(-1) in both hyperthermia-treated and untreated spheroids. For groups receiving hyperthermia, no increase in cytotoxicity was seen compared with normothermic controls at any activity concentration. These results and those from autoradiographs indicate that hyperthermia at 42 degrees C for 1 h had no significant effect on the uptake or distribution of this antitenascin MAb in D-247 MG spheroids.Keywords
This publication has 29 references indexed in Scilit:
- Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convectionPublished by Elsevier ,2004
- The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibodyNuclear Medicine and Biology, 1996
- Radioimmunotherapy of prostatic adenocarcinomas: Effects of 131I‐labelled E4 antibodies on cells at different depth in DU 145 spheroidsInternational Journal of Cancer, 1995
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary reportJournal of Neuro-Oncology, 1995
- Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascinJournal of Neuroimmunology, 1994
- Effect of cell arrangement and interstitial volume fraction on the diffusivity of monoclonal antibodies in tissueBiophysical Journal, 1993
- Elimination of dose-rate effects by mild hyperthermiaInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Hyperthermia-induced shedding and masking of melanoma-associated antigenInternational Journal of Hyperthermia, 1990
- The effects of hyperthermia on tumor carcinoembryonic antigen expressionInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978